Symbiotec Pharmalab IPO Opens Today: Check Price Band, Lot Size, Dates

MUMBAI — Research-driven active pharmaceutical ingredient (API) manufacturer Symbiotec Pharmalab Limited opened its initial public offering (IPO) for public subscription on Monday, August 24, 2026. The ₹1,757 crore book-built offer will remain open for retail, non-institutional, and qualified institutional buyers until Thursday, August 27, 2026.

The public issue comes as investors evaluate expanding opportunities in India's specialty pharmaceutical and generic drug export sectors. Prior to the opening, the company raised ₹526.20 crore from anchor investors on August 21, 2026.

Price Band, Issue Structure, and Minimum Investment Details

Symbiotec Pharmalab has fixed the price band for the public offering at ₹938 to ₹988 per equity share of face value ₹2 each. The total issue size of ₹1,757 crore includes a fresh issue of shares worth up to ₹150 crore and an Offer for Sale (OFS) of up to ₹1,607 crore by existing shareholders and promoter entities.

Retail individual investors can apply in minimum lots of 15 shares, requiring a minimum investment of ₹14,820 calculated at the upper price band of ₹988. The maximum bid for retail investors is capped at 13 lots (195 shares) amounting to ₹1,92,660.

Proceeds Utilization and Financial Performance Overview

According to the Red Herring Prospectus (RHP), net proceeds from the fresh capital issue amounting to ₹112.50 crore will be utilized toward the prepayment or partial repayment of outstanding debts incurred by the company, while the remaining balance will support general corporate objectives. Proceeds from the Offer for Sale will go directly to the selling shareholders.

In Fiscal 2026, Symbiotec Pharmalab reported operational revenue of ₹869.15 crore, compared to ₹751.55 crore in Fiscal 2025 and ₹716.25 crore in Fiscal 2024. Net profit after tax (PAT) for FY26 stood at ₹109.90 crore, up from ₹96.79 crore in FY25.

Official Sources

According to regulatory disclosures in the Red Herring Prospectus filed with the Securities and Exchange Board of India (SEBI), the offering is managed by lead managers including JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, and Nomura Financial Advisory and Securities (India) Private Limited.

Listing applications have been submitted to the National Stock Exchange of India (NSE) and the BSE India, with MUFG Intime India Private Limited acting as the official registrar to the issue.

Official Quotes

"According to officials in the Red Herring Prospectus, the net proceeds from the fresh equity issue will assist the company in reducing overall debt obligations and strengthening capital efficiency across operating units," stated market documents registered with market regulators.

Lead managers noted that the book-building process reflects active participation across qualified institutional buyers, non-institutional investors, and retail categories.

Why It Matters

For retail equity investors and capital market participants, the Symbiotec Pharmalab IPO offers exposure to an established API manufacturer holding significant global volume shares in corticosteroids and steroidal-hormone active ingredients.

The company's performance, post-issue capital structure, and primary debt-reduction strategy remain critical indicators for evaluating long-term valuation prospects in the pharmaceutical manufacturing sector.

Key Facts at a Glance

• Issue Window: Subscription opens August 24, 2026, and closes August 27, 2026.

• Price Band: Fixed between ₹938 and ₹988 per equity share.

• Minimum Application: Retail investors can bid for a lot size of 15 shares (minimum ₹14,820).

• Issue Size: Total offer of ₹1,757 crore (₹150 crore fresh issue + ₹1,607 crore OFS).

• Listing Details: Tentative listing scheduled on BSE and NSE for September 1, 2026.

Frequently Asked Questions (FAQ)

What are the subscription dates for the Symbiotec Pharmalab IPO?

The IPO opens for public bidding on August 24, 2026, and closes on August 27, 2026.

What is the lot size and minimum investment required?

The minimum lot size is 15 equity shares. At the upper price band of ₹988 per share, a retail investor requires a minimum investment of ₹14,820.

When is the tentative share allotment and listing date?

The basis of share allotment is expected to be finalized on August 28, 2026, with tentative listing on BSE and NSE on September 1, 2026.

Source: Securities and Exchange Board of India (SEBI), National Stock Exchange of India (NSE), BSE India, Chittorgarh IPO Portal.